REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a privately-held women’s healthcare medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that with the support of the American College of
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that its Sonata® Procedure has been used to treat over 1,000 women in the United
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids is Now Covered by UnitedHealthcare
REDWOOD CITY, CA, August 1, 2023 – Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that its Sonata® Procedure is now covered by UnitedHealthcare, effective August 1, 2023.
GYNESONICS NAMES INDUSTRY VETERAN SKIP BALDINO PRESIDENT AND CEO, ANNOUNCES $25M FINANCING TO EXPAND WORLDWIDE COMMERCIALIZATION
REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced that Skip Baldino was appointed in early March to the role of President and Chief Executive
Gynesonics Announces First Office-Based Sonata Procedure in the State of Texas
Dr. John Thoppil, Current President of the Texas Association of Obstetricians and Gynecologists (TAOG), Performs Sonata Procedure in Austin Redwood City, CA, October 5, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic
Gynesonics Names Robert Brown Chief Financial Officer
Redwood City, CA, September 29, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Robert Brown has joined the company as Chief Financial Officer, starting immediately. Mr. Brown’s
Gynesonics Announces FDA Clearance of Next Generation Sonata System
The Only Transcervical, Incisionless System for Radiofrequency Ablation of Fibroids Provides New Benefits through Features Such as Increased Range of Ablation Sizes, a New User Interface, and Validation of Additional Low Temperature Hospital Reprocessing Systems Redwood City, CA, September 16, 2021
Gynesonics Announces Anthem, the Second Largest Healthcare Payer in the U.S., Issues Medical Necessity Coverage for the Treatment of Symptomatic Uterine Fibroids with the Sonata Procedure
Anthem’s decision significantly increases nationwide access for Sonata Redwood City, CA, September 14, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced Anthem, Inc., the largest managed health